

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan and to the deferral.

MHRA-100249-PIP01-21-M04

Scope of the Application

Active Substance(s)

BUDESONIDE; GLYCOPYRRONIUM; FORMOTEROL FUMARATE DIHYDRATE

Condition(s)

Treatment of asthma

Pharmaceutical Form(s)

Pressurised inhalation, suspension

Route(s) of Administration

INHALATION USE

Name / Corporate name of the PIP applicant

AstraZeneca UK Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, AstraZeneca UK Limited submitted to the licensing authority on 09/12/2025 17:46 GMT an application for a Modification

The procedure started on 16/01/2026 10:10 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100249-PIP01-21-M04

Of 24/02/2026 14:08 GMT

On the adopted decision for BUDESONIDE; GLYCOPYRRONIUM; FORMOTEROL FUMARATE DIHYDRATE (MHRA-100249-PIP01-21-M04) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan).

This decision applies to a Modification for BUDESONIDE; GLYCOPYRRONIUM; FORMOTEROL FUMARATE DIHYDRATE, Pressurised inhalation, suspension , INHALATION USE .

This decision is addressed to AstraZeneca UK Limited, 2 Pancras Square, London, UNITED KINGDOM, N1C 4AG

ANNEX I

1. Waiver

1.1 Condition:

Treatment of asthma The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 4 years of age. Pharmaceutical form(s): Pressurised inhalation, suspension Route(s) of administration: INHALATION USE Reason for granting waiver: On the grounds the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of asthma

2.2 Indication(s) targeted by the PIP:

For the regular treatment of asthma in children and adolescents from 4 years to less than 18 years of age where use of a triple combination medicinal product is appropriate.

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 4 years to less than 18 years of age

2.4 Pharmaceutical Form(s):

Pressurised inhalation, suspension

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not applicable.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	6	Study 1 (PT001102) Multi-centre, randomised, double-blind, parallel-group, placebo-controlled, 6-month dose confirmation study to evaluate the efficacy and safety of 3 doses of glycopyrronium (GP) metered dose inhaler (MDI) and open label Spiriva Respimat compared to placebo MDI, in symptomatic adolescents (and adults) with asthma receiving low to high-dose inhaled corticosteroids (ICS)/ long-acting beta agonists (LABA). Study 2 (PT010102; D5982C00007; KALOS) Randomised, double-blind, double-dummy, active-controlled parallel-group, multicentre study to assess the effects of budesonide, glycopyrronium and formoterol fumarate inhalation suspension [BGF metered dose inhaler (MDI)] relative to budesonide and formoterol fumarate inhalation suspension (BFF) and Symbicort on lung function, moderate to severe exacerbation, symptoms and Quality of Life (QoL) over a 24-52 week variable length period in adolescents

		from 12 years to less than 18 years of age (and adults) with severe persistent asthma, and the steady state pharmacokinetics in a substudy. Study 3 (PT010103; D5982C00008; LOGOS) Randomised, double-blind, double-dummy, active-controlled, parallel group, 24-52 week, variable length study to assess the efficacy and safety of BGF MDI compared to BFF MDI and open-label Symbicort, as an active control, on lung function, asthma exacerbations, symptoms and Quality of Life (QoL) in adolescent (and adult) subjects with asthma. Study 4 Randomised, double-blind, placebo-controlled, chronic dosing (3 weeks), 6-period crossover study comparing the efficacy and safety of 3 doses of Glycopyrronium Inhalation Suspension (GP MDI) with placebo MDI in children 4 years to less than 12 years of age with asthma.
Extrapolation, Modeling & Simulation Studies	0	Not applicable.
Other Studies	0	Not applicable.
Other Measures	0	Clinical Studies continued: Study 5 Randomised, double-blind, parallel group, 24-52 week, variable length study with an open-label arm to assess the efficacy and safety of BGF MDI compared to BFF MDI on lung function and on moderate/severe asthma exacerbations in subjects from 4 years to less than 18 years of age with asthma. Study 6 Open-label, single-period, single-centre, single-dose study to assess the pharmacokinetics (PK) of BGF MDI in subjects from 4 years to less than 18 years of age with asthma.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	31/10/2031
Deferral of one or more studies contained in the paediatric investigation plan:	Yes

